Tenet Healthcare Corporation logo

Tenet Healthcare Corporation (THC)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
267. 25
-7.88
-2.8641%
$
22.15B Market Cap
17.14 P/E Ratio
- Div Yield
827,555 Volume
6.03 Eps
$ 275.13
Previous Close
Add Transaction
Day Range
265.6 277.37
Year Range
157.58 283.05
Want to track THC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Here's Why Tenet Healthcare (THC) is a Strong Value Stock

Here's Why Tenet Healthcare (THC) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It

Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It

Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock

Here's Why Tenet Healthcare (THC) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Is It Worth Investing in Tenet (THC) Based on Wall Street's Bullish Views?

Is It Worth Investing in Tenet (THC) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks | 1 year ago
Is Tenet Healthcare (THC) Stock Undervalued Right Now?

Is Tenet Healthcare (THC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Tenet (THC)

Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Tenet (THC)

Tenet (THC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks | 1 year ago
Is the Options Market Predicting a Spike in Tenet Healthcare Stock?

Is the Options Market Predicting a Spike in Tenet Healthcare Stock?

Investors need to pay close attention to THC stock based on the movements in the options market lately.

Zacks | 1 year ago
Tenet Healthcare Continues To Win In Q2, But Medicaid Cuts May Threaten Growth Beyond 2026

Tenet Healthcare Continues To Win In Q2, But Medicaid Cuts May Threaten Growth Beyond 2026

Tenet Healthcare remains a buy, consistently beating earnings and raising guidance, even as the healthcare sector faces broad pressure from looming Medicaid cuts. Ambulatory segment growth is key, as it is higher margin and less exposed to Medicaid risk than the hospital segment, which faces headwinds post-2026. Medicaid cuts are now law and will hit hardest after 2026, posing significant long-term risk to hospital revenues despite Tenet's restructuring efforts.

Seekingalpha | 1 year ago
Tenet Healthcare Corporation (THC) Q2 2025 Earnings Call Transcript

Tenet Healthcare Corporation (THC) Q2 2025 Earnings Call Transcript

Tenet Healthcare Corporation (NYSE:THC ) Q2 2025 Earnings Conference Call July 22, 2025 10:00 AM ET Company Participants William McDowell - Vice President of Investor Relations Saumya Sutaria - Chairman & CEO Sun Park - Executive VP & CFO Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Joshua Raskin - Nephron Research LLC Andrew Mok - Barclays Bank PLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Justin Lake - Wolfe Research, LLC Sarah James - Cantor Fitzgerald & Co., Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Ryan Langston - TD Cowen, Research Division John Ransom - Raymond James & Associates, Inc., Research Division Kevin Fischbeck - BofA Securities, Research Division Operator Good morning. Welcome to Tenet Healthcare Second Quarter 2025 Earnings Conference Call.

Seekingalpha | 1 year ago
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View

THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.

Zacks | 1 year ago
Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Tenet Healthcare (THC) Beats Q2 Earnings and Revenue Estimates

Tenet Healthcare (THC) Beats Q2 Earnings and Revenue Estimates

Tenet Healthcare (THC) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $2.84 per share. This compares to earnings of $2.31 per share a year ago.

Zacks | 1 year ago
Loading...
Load More